Cargando…
Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435779/ https://www.ncbi.nlm.nih.gov/pubmed/34527705 http://dx.doi.org/10.3389/fmolb.2021.727969 |
| _version_ | 1783751870175510528 |
|---|---|
| author | Zhang, Lei Yan, Zhi-Ping Hou, Zhong-Heng Huang, Peng Yang, Min-Jie Zhang, Shuai Zhang, Shen Zhang, Shao-Hua Zhu, Xiao-Li Ni, Cai-Fang Li, Qiang |
| author_facet | Zhang, Lei Yan, Zhi-Ping Hou, Zhong-Heng Huang, Peng Yang, Min-Jie Zhang, Shuai Zhang, Shen Zhang, Shao-Hua Zhu, Xiao-Li Ni, Cai-Fang Li, Qiang |
| author_sort | Zhang, Lei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8435779 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84357792021-09-14 Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib Zhang, Lei Yan, Zhi-Ping Hou, Zhong-Heng Huang, Peng Yang, Min-Jie Zhang, Shuai Zhang, Shen Zhang, Shao-Hua Zhu, Xiao-Li Ni, Cai-Fang Li, Qiang Front Mol Biosci Molecular Biosciences Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435779/ /pubmed/34527705 http://dx.doi.org/10.3389/fmolb.2021.727969 Text en Copyright © 2021 Zhang, Yan, Hou, Huang, Yang, Zhang, Zhang, Zhang, Zhu, Ni and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Molecular Biosciences Zhang, Lei Yan, Zhi-Ping Hou, Zhong-Heng Huang, Peng Yang, Min-Jie Zhang, Shuai Zhang, Shen Zhang, Shao-Hua Zhu, Xiao-Li Ni, Cai-Fang Li, Qiang Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title | Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title_full | Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title_fullStr | Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title_full_unstemmed | Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title_short | Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib |
| title_sort | corrigendum: neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus sorafenib |
| topic | Molecular Biosciences |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435779/ https://www.ncbi.nlm.nih.gov/pubmed/34527705 http://dx.doi.org/10.3389/fmolb.2021.727969 |
| work_keys_str_mv | AT zhanglei corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT yanzhiping corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT houzhongheng corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT huangpeng corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT yangminjie corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT zhangshuai corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT zhangshen corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT zhangshaohua corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT zhuxiaoli corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT nicaifang corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib AT liqiang corrigendumneutrophiltolymphocyteandplatelettolymphocyteratiosaspredictorsofoutcomesinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationplussorafenib |